Lung Cancer: Targets and Therapy最新文献

{"title":"Uncommon <i>EGFR</i> mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients.","authors":"Elisna Syahruddin,&nbsp;Laksmi Wulandari,&nbsp;Nunuk Sri Muktiati,&nbsp;Ana Rima,&nbsp;Noni Soeroso,&nbsp;Sabrina Ermayanti,&nbsp;Michael Levi,&nbsp;Heriawaty Hidajat,&nbsp;Grace Widjajahakim,&nbsp;Ahmad Rusdan Handoyo Utomo","doi":"10.2147/LCTT.S154116","DOIUrl":"https://doi.org/10.2147/LCTT.S154116","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to evaluate the distribution of individual epidermal growth factor receptor (<i>EGFR</i>) mutation subtypes found in routine cytological specimens.</p><p><strong>Patients and methods: </strong>A retrospective audit was performed on <i>EGFR</i> testing results of 1,874 consecutive cytological samples of newly diagnosed or treatment-naïve Indonesian lung cancer patients (years 2015-2016). Testing was performed by ISO15189 accredited central laboratory.</p><p><strong>Results: </strong>Overall test failure rate was 5.1%, with the highest failure (7.1%) observed in pleural effusion and lowest (1.6%) in needle aspiration samples. <i>EGFR</i> mutation frequency was 44.4%. Tyrosine kinase inhibitor (TKI)-sensitive common <i>EGFR</i> mutations (ins/dels exon 19, L858R) and uncommon mutations (G719X, T790M, L861Q) contributed 57.1% and 29%, respectively. Approximately 13.9% of mutation-positive patients carried a mixture of common and uncommon mutations. Women had higher <i>EGFR</i> mutation rate (52.9%) vs men (39.1%; <i>p</i><0.05). In contrast, uncommon mutations conferring either TKI responsive (G719X, L861Q) or TKI resistance (T790M, exon 20 insertions) were consistently more frequent in men than in women (67.3% vs 32.7% or 69.4% vs 30.6%; <i>p</i><0.05). Up to 10% <i>EGFR</i> mutation-positive patients had baseline single mutation T790M, exon 20 insertion, or in coexistence with TKI-sensitive mutations. Up to 9% patients had complex or multiple <i>EGFR</i> mutations, whereby 48.7% patients harbored TKI-resistant mutations. One patient presented third-generation TKI-resistant mutation L792F simultaneously with T790M.</p><p><strong>Conclusion: </strong>Routine diagnostic cytological techniques yielded similar success rate to detect <i>EGFR</i> mutations. Uncommon <i>EGFR</i> mutations were frequent events in Indonesian lung cancer patients.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"9 ","pages":"25-34"},"PeriodicalIF":3.6,"publicationDate":"2018-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S154116","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35976228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives.","authors":"Elysia K Donovan,&nbsp;Anand Swaminath","doi":"10.2147/LCTT.S129833","DOIUrl":"https://doi.org/10.2147/LCTT.S129833","url":null,"abstract":"<p><p>Stereotactic body radiation therapy (SBRT) has emerged as a new technology in radiotherapy delivery, allowing for potentially curative treatment in many patients previously felt not to be candidates for radical surgical resection of stage I non-small-cell lung cancer (NSCLC). Several studies have demonstrated very high local control rates using SBRT, and more recent data have suggested overall survival may approach that of surgery in operable patients. However, SBRT is not without unique toxicities, and the balance of toxicity, and effect on patient-reported quality of life need to be considered with respect to oncologic outcomes. We therefore aim to review SBRT in the context of important patient-related factors, including quality of life in several domains (and in comparison to other therapies such as conventional radiation, surgery, or no treatment). We will also describe scenarios in which SBRT may be reasonably offered (i.e. elderly patients and those with severe COPD), and where it may need to be approached with some caution due to increased risks of toxicity (i.e. tumor location, patients with interstitial lung disease). In total, we hope to characterize the physical, emotional, and functional consequences of SBRT, in relation to other management strategies, in order to aid the clinician in deciding whether SBRT is the optimal treatment choice for each patient with early stage NSCLC.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"9 ","pages":"13-23"},"PeriodicalIF":3.6,"publicationDate":"2018-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S129833","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35956431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer.","authors":"Vidya H Veldore,&nbsp;Anuradha Choughule,&nbsp;Tejaswi Routhu,&nbsp;Nitin Mandloi,&nbsp;Vanita Noronha,&nbsp;Amit Joshi,&nbsp;Amit Dutt,&nbsp;Ravi Gupta,&nbsp;Ramprasad Vedam,&nbsp;Kumar Prabhash","doi":"10.2147/LCTT.S147841","DOIUrl":"https://doi.org/10.2147/LCTT.S147841","url":null,"abstract":"<p><p>Plasma cell-free tumor DNA, or circulating tumor DNA (ctDNA), from liquid biopsy is a potential source of tumor genetic material, in the absence of tissue biopsy, for <i>EGFR</i> testing. Our validation study reiterates the clinical utility of ctDNA next generation sequencing (NGS) for EGFR mutation testing in non-small cell lung cancer (NSCLC). A total of 163 NSCLC cases were included in the validation, of which 132 patients had paired tissue biopsy and ctDNA. We chose to validate ctDNA using deep sequencing with custom designed bioinformatics methods that could detect somatic mutations at allele frequencies as low as 0.01%. Benchmarking allele specific real time PCR as one of the standard methods for tissue-based <i>EGFR</i> mutation testing, the ctDNA NGS test was validated on all the plasma derived cell-free DNA samples. We observed a high concordance (96.96%) between tissue biopsy and ctDNA for oncogenic driver mutations in Exon 19 and Exon 21 of the <i>EGFR</i> gene. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the assay were 91.1%, 100% 100%, 95.6%, and 97%, respectively. A false negative rate of 3% was observed. A subset of mutations was also verified on droplet digital PCR. Sixteen percent EGFR mutation positivity was observed in patients where only liquid biopsy was available, thus creating options for targeted therapy. This is the first and largest study from India, demonstrating successful validation of circulating cell-free DNA as a clinically useful material for molecular testing in NSCLC.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"9 ","pages":"1-11"},"PeriodicalIF":3.6,"publicationDate":"2018-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S147841","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35776290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer.","authors":"Seigo Minami,&nbsp;Yoshitaka Ogata,&nbsp;Shouichi Ihara,&nbsp;Suguru Yamamoto,&nbsp;Kiyoshi Komuta","doi":"10.2147/LCTT.S142880","DOIUrl":"https://doi.org/10.2147/LCTT.S142880","url":null,"abstract":"<p><strong>Background: </strong>Various biomarkers have been shown to predict prognosis in various types of cancers. However, these biomarkers have not been studied in advanced small cell lung cancer (SCLC). The modified Glasgow prognostic score (mGPS) is based on serum albumin level and C-reactive protein (CRP). The prognostic nutritional index (PNI) is a combination of serum albumin level and absolute lymphocyte count. This study aimed to evaluate the prognostic value of mGPS and PNI in SCLC.</p><p><strong>Methods: </strong>We retrospectively reviewed and calculated mGPS and PNI for patients with stage IIIB or IV SCLC who initiated platinum-based combination chemotherapy between November 2007 and June 2016. We compared overall survival (OS) and progression-free survival (PFS) between high and low groups of these two biomarkers. Univariate and multivariate Cox hazard analyses assessed the prognostic value of these biomarkers.</p><p><strong>Results: </strong>We reviewed 97 SCLC patients. The OS of patients with mGPS 0-1 and higher PNI was significantly longer than that of those with mGPS 2 and lower PNI. The PFS of mGPS 0-1 was significantly longer than that of mGPS 2, while there was no significant difference in PFS according to PNI. Multivariate analyses found mGPS 0-1 (hazard ratio [HR] 2.34, 95% confidence interval [CI] 1.27-4.31, <i>P</i><0.01) and higher PNI (HR 0.50, 95% CI 0.31-0.78, <i>P</i><0.01) as prognostic factors for longer OS. However, neither biomarker was predictive of PFS.</p><p><strong>Conclusion: </strong>Our study was a small retrospective study; however, the data demonstrate that pretreatment mGPS and PNI are independent predictors of OS in patients with advanced SCLC. The pretreatment assessment of mGPS and PNI may be useful for identification of patients with poor prognosis. We recommend pretreatment measurement of serum albumin, C-reactive protein, and absolute lymphocyte count.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"8 ","pages":"249-257"},"PeriodicalIF":3.6,"publicationDate":"2017-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S142880","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35676229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Cis</i>-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.","authors":"Samuel J Klempner,&nbsp;Pareen Mehta,&nbsp;Alexa B Schrock,&nbsp;Siraj M Ali,&nbsp;Sai-Hong Ignatius Ou","doi":"10.2147/LCTT.S147129","DOIUrl":"https://doi.org/10.2147/LCTT.S147129","url":null,"abstract":"<p><p>Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clinical efficacy. The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-small-cell lung cancer. Mechanisms of acquired resistance are emerging, and here we describe a <i>cis</i>-oriented solvent-front EGFR G796S mutation as the resistance mechanism observed in a progression biopsy and circulating tumor DNA (ctDNA) from a patient with initial response followed by progression on osimertinib. This is one of the earliest reports of a sole solvent-front tertiary EGFR mutation as a resistance mechanism to osimertinib. Our case suggests a monoclonal resistance mechanism. We review the importance of the solvent-front residues across TKIs and describe known osimertinib resistance mechanisms. We observe that nearly all clinical osimertinib-resistant tertiary EGFR mutations are oriented in <i>cis</i> with EGFR T790M. This case highlights the importance of mutations affecting EGFR kinase domains and supports the feasibility of broad panel ctDNA assays for detection of novel acquired resistance and tumor heterogeneity in routine clinical care.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"8 ","pages":"241-247"},"PeriodicalIF":3.6,"publicationDate":"2017-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S147129","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35669050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response.","authors":"Ewa Wojcik,&nbsp;Jan Kanty Kulpa","doi":"10.2147/LCTT.S149516","DOIUrl":"https://doi.org/10.2147/LCTT.S149516","url":null,"abstract":"<p><p>Lung cancer belongs to malignant tumors that possess the highest rates of morbidity and mortality in the world. A number of morphological, biological and clinical features justify the distinction of small-cell carcinoma with respect to the other histological types of lung cancer. The predominant neuroendocrine phenotype is critical for the selection of biomarkers used in diagnostics, monitoring and evaluation of treatment response; early onset relapses in patients with small-cell lung cancer (SCLC) and the evaluation of their prognosis. Although for a long time the neuron-specific enolase (NSE) was considered to be the marker of choice for this tumor, it is now increasingly important to pay attention to concentrations of pro-gastrin-releasing peptide (ProGRP). The results of this marker have been implicated in the differential diagnosis of non-small lung cancer and SCLC, chemotherapy and radiotherapy monitoring as well as evaluation of treatment response. The subject of this series of studies is to determine the usefulness of ProGRP in the evaluation of patients' prognosis and its predictive value. The current aim for the optimization of the effectiveness of biochemical diagnostics of SCLC is recommended by complementary ProGRP and NSE studies. The present work is a summary of the latest reports regarding diagnostic utility of these markers in SCLC.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"8 ","pages":"231-240"},"PeriodicalIF":3.6,"publicationDate":"2017-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S149516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35653836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.","authors":"Wolfgang Schuette,&nbsp;Claus-Peter Schneider,&nbsp;Walburga Engel-Riedel,&nbsp;Christian Schumann,&nbsp;Martin Kohlhaeufl,&nbsp;Monika Heidi Ursel Serke,&nbsp;Gert Hoeffken,&nbsp;Cornelius Kortsik,&nbsp;Martin Reck","doi":"10.2147/LCTT.S142972","DOIUrl":"https://doi.org/10.2147/LCTT.S142972","url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to investigate in terms of noninferiority the efficacy and safety of a monochemotherapy regimen of pemetrexed plus bevacizumab (BevPem) versus carboplatin/pemetrexed plus bevacizumab (BevCPem) in elderly patients as first-line treatment for advanced metastatic or recurrent nonsquamous non-small-cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>65Plus was a Phase III, randomized, open-label study. In total, 253 patients received BevPem (n=119) or BevCPem (n=134). The primary outcome measure was progression-free survival. Secondary end points were overall survival, tumor response, and safety outcomes. Evaluations were performed for the whole study population and stratified according to Eastern Cooperative Oncology Group (ECOG) performance status (PS).</p><p><strong>Results: </strong>Noninferiority of BevPem in comparison to BevCPem could not be demonstrated for the overall population (<i>P</i>=0.7864). Significant superiority of the combined treatment BevCPem was seen in patients of ECOG PS 0-1 (median PFS 5.1 vs 6.9 months, HR 1.353, 95% CI 1.03-1.777), while the opposite tendency was observed in patients with ECOG PS 2 (median PFS 2.9 vs 1.5 months, HR 0.628, 95% CI 0.195-2.025). Overall, better tolerability was found for the BevPem group, irrespective of ECOG PS.</p><p><strong>Conclusion: </strong>Results from the 65plus study give evidence that BevPem and BevCPem treatments may exert differential effects on PFS, depending on the patients ECOG PS. It appears that patients with better ECOG PS (0-1) benefited more from the combined treatment with carboplatin, while the group comprising more severely impaired patients (ECOG PS 2) benefited more from the monochemotherapy.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"8 ","pages":"217-229"},"PeriodicalIF":3.6,"publicationDate":"2017-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S142972","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35624551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>nab</i>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.","authors":"Michael Thomas,&nbsp;David R Spigel,&nbsp;Robert M Jotte,&nbsp;Michael McCleod,&nbsp;Mark A Socinski,&nbsp;Ray D Page,&nbsp;Laurent Gressot,&nbsp;Jeanna Knoble,&nbsp;Oscar Juan,&nbsp;Daniel Morgensztern,&nbsp;Dolores Isla,&nbsp;Edward S Kim,&nbsp;Howard West,&nbsp;Amy Ko,&nbsp;Teng Jin Ong,&nbsp;Nataliya Trunova,&nbsp;Cesare Gridelli","doi":"10.2147/LCTT.S138570","DOIUrl":"https://doi.org/10.2147/LCTT.S138570","url":null,"abstract":"<p><strong>Background: </strong>Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of <i>nab</i>-paclitaxel/carboplatin combination chemotherapy.</p><p><strong>Methods: </strong>Patients received <i>nab</i>-paclitaxel 100 mg/m² days 1, 8, 15 + carboplatin area under the curve 6 mg•min/mL day 1 (q3w) for four cycles. QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and Euro-QoL-5 Dimensions-5 Levels (EQ-5D-5L) at baseline and each cycle (day 1).</p><p><strong>Results: </strong>Two-hundred and six lesion-response-evaluable patients completed baseline + ≥1 postbaseline QoL assessment and were QoL evaluable. LCSS average total score and symptom burden index improved from baseline throughout four cycles. In the LCSS pulmonary symptoms score, 46% of patients reported clinically meaningful improvement (≥10 mm visual analog scale) from baseline. Individual EQ-5D-5L dimensions remained stable/improved in ≥83% of patients; ≈33% reported complete resolution of baseline problems at least once during four cycles. Generally, responders (unconfirmed complete/partial response) had higher scores vs nonresponders.</p><p><strong>Conclusion: </strong>In patients with squamous NSCLC, four cycles of <i>nab</i>-paclitaxel/carboplatin demonstrated clinically meaningful QoL improvements, with greater benefits in responders vs nonresponders.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"8 ","pages":"207-216"},"PeriodicalIF":3.6,"publicationDate":"2017-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S138570","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35606474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan.","authors":"Hiroshi Isobe,&nbsp;Kiyoshi Mori,&nbsp;Koichi Minato,&nbsp;Hideki Katsura,&nbsp;Kazuko Taniguchi,&nbsp;Ashwini Arunachalam,&nbsp;Smita Kothari,&nbsp;Xiting Cao,&nbsp;Terufumi Kato","doi":"10.2147/LCTT.S140491","DOIUrl":"https://doi.org/10.2147/LCTT.S140491","url":null,"abstract":"<p><strong>Background: </strong>Recommended therapies for advanced/metastatic non-small cell lung cancer (NSCLC) have changed with the advent of targeted therapies. The objectives of this retrospective chart review study were to describe treatment patterns, biomarker testing practices, and health care resource use for advanced NSCLC at 5 sites in Japan.</p><p><strong>Patients and methods: </strong>We studied anonymized medical record data of patients aged ≥18 years who initiated systemic therapy for newly diagnosed stage IIIB or IV NSCLC from January 2011 through June 2013. Data were analyzed descriptively by histology and mutation status. Overall survival was estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>We studied 175 patients, including 43 (25%), 129 (74%), and 3 (2%) with squamous, nonsquamous, and unknown NSCLC histology, respectively; 83% had stage IV NSCLC. Overall, 123 patients (70%) were male; the median age was 70 years (range, 47-86); and 33 (19%) were never-smokers. In the nonsquamous cohort, 105 (81%) and 25 (19%) of patients were tested for epidermal growth factor receptor (<i>EGFR</i>) mutation and anaplastic lymphoma kinase (<i>ALK</i>) rearrangement, respectively; 44 (42%) had <i>EGFR</i>-positive NSCLC and 2 (8%) had <i>ALK</i>-positive NSCLC, including 26/46 (57%) women and 21/46 (46%) never-smokers. In the squamous cohort, 17 (40%) and 4 (9%), respectively, were tested; 1 <i>EGFR</i>-positive tumor was detected. After first-line therapy, 105 (60%) patients received second-line, and 54/105 (51%; or 31% overall) received third-line therapy. <i>EGFR</i> tyrosine kinase inhibitors were most commonly prescribed for <i>EGFR</i>-positive NSCLC across all lines. In the nonsquamous <i>EGFR</i>/<i>ALK</i>-negative/unknown cohort, most received first-line platinum combinations, particularly younger patients (78% ≥75 years vs 93% <75 years old). The average hospitalization was 21 days/admission. The median (95% CI) overall survival from start of first-line therapy was 9.9 months (7.6-11.7) for all patients and 17.9 months (9.9-24.4) for patients with <i>EGFR</i>/<i>ALK</i>-positive status.</p><p><strong>Conclusion: </strong>Biomarker testing is common for nonsquamous NSCLC at the 5 Japanese study sites. Treatment is personalized by mutation status and age, per guideline recommendations.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"8 ","pages":"191-206"},"PeriodicalIF":3.6,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S140491","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35594184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of soluble major histocompatibility complex class I polypeptide-related sequence A in non-small-cell lung cancer - significance and development.","authors":"Roberto Cascone,&nbsp;Annalisa Carlucci,&nbsp;Matteo Pierdiluca,&nbsp;Mario Santini,&nbsp;Alfonso Fiorelli","doi":"10.2147/LCTT.S105623","DOIUrl":"https://doi.org/10.2147/LCTT.S105623","url":null,"abstract":"<p><p>Soluble major histocompatibility complex class I polypeptide-related sequence A (sMICA) is a useful marker in surveillance of lung cancer. High serum sMICA level in patients with non-small-cell lung cancer (NSCLC) seems to be a poor prognostic factor being correlated with poor differentiation and advanced stage. However, the low specificity limits its role as a single prognostic marker of NSCLC, but its evaluation, in addition to standard serum markers, could improve the staging of NSCLC. Despite promising, all current studies are insufficient to assess the real efficiency of sMICA as a prognostic marker of NSCLC, and hence, future studies are required to validate it.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"8 ","pages":"161-167"},"PeriodicalIF":3.6,"publicationDate":"2017-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S105623","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35480998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}